3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Melanoma
8
Carcinoma, Non-Small-Cell Lung
8
Carcinoma, Hepatocellular
8
Squamous Cell Carcinoma of Head and Neck
6
Small Cell Lung Carcinoma
5
Neoplasms
4
Lung Neoplasms
4
Prostatic Neoplasms
3
Diabetes Mellitus, Insulin-Dependent, 12
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Advanced Solid Tumors
3
Urinary Bladder Neoplasms
2
Recurrence
2
Lymphoma, Large B-Cell, Diffuse
2
Liver Neoplasms
2
Head and Neck Neoplasms
2
Biliary Tract Neoplasms
2
Urothelial Cancer
1
Unresectable Hepatocellular Carcinoma
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Peritoneal Neoplasms
1
Part A and B: Advanced Solid Malignancies
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non Small Cell Lung Cancer NSCLC
1
Non - Small Cell Lung Cancer NSCLC
1
Interventions
Pemetrexed
13
Cisplatin
12
Nivolumab
5
Carboplatin
5
pembrolizumab
4
Ipilimumab
4
Cyclophosphamide
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
fludarabine
3
defactinib
3
amatuximab
2
Paclitaxel
2
Gemcitabine
2
Drug Therapy
2
tremelimumab
1
tazemetostat
1
osimertinib
1
napabucasin
1
enzalutamide
1
bemcentinib
1
abemaciclib
1
VS-5584
1
Trabectedin
1
Thiostrepton
1
Safety
1
Panobinostat
1
Monatide (IMS 3015)
1
Midazolam
1
Letrozole
1
LY3023414
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mesothelioma, Malignant
×
tremelimumab
×
Clear all
NCT01843374
2026-03-05
Tremelimumab
MedImmune LLC
Phase 2
Active not recruiting
571 enrolled
19 charts